Monopar Therapeutics MNPR
NASDAQ MNPR
$77.97 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT

Monopar Therapeutics (MNPR) Non Operating Investment Income (2023)

Updated

Monopar Therapeutics (MNPR) reported Non Operating Investment Income of $33,645 for Q1 2023.

Analysis

Monopar Therapeutics (MNPR) Non Operating Investment Income (2023) Analysis & Trends

For FY2022, Monopar Therapeutics posted Non Operating Investment Income of $15,039.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Op. Investment Inc. (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn -
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn -
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn -
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn -
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn -
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn -
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn -
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn -
10 Monopar Therapeutics 666.05 Mn 384.28 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2023 33,645.00
API Access

Monopar Therapeutics Non Operating Investment Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-investment-income&ticker=MNPR&period=max&api_key=YOUR_API_KEY